
    
      The study will consist of a treatment phase and follow-up phase. The treatment period is 12
      months. Discontinuation of study treatment may occur earlier than 12 months for disease
      recurrence, death, unacceptable toxicity or withdrawal of consent. Patients will be followed
      for disease recurrence every 6 months and up to 24 months after the end of treatment (EOT)
    
  